drugset / Trial / NCT00969982

Mifepristone Plus Misoprostol Versus Misoprostol Alone for 2nd Trimester Abortion (14 - 21 Weeks Last Menstrual Period (LMP))

NCT00969982

Completed 238 enrolled Gynuity Health Projects
RandomizedParallel-groupTriple-blindTreatment

Summary

The primary goal of this study is to determine the clinical advantage of pre-treatment with mifepristone in second trimester misoprostol induction abortion. This will be a randomized controlled double-blinded trial of 120 women in each country comparing misoprostol alone to mifepristone plus misoprostol for second trimester (14-21 weeks' LMP) medical abortion.

Timeline

Start
2009-06
Primary completion
2013-06
Completion
2013-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Mifepristone Small molecule 200 mg
Subject Misoprostol Other / unclassified 800 ug Other

Indications

No indication recorded.